Encebrain

5 ml suspension contains:

• Active ingredient: pyritinol 80.5 mg, which corresponds to the content of pyritinol dihydrochloride monohydrate 100 mg.

• symptomatic treatment of dementia syndrome ( including primary degenerative dementia, vascular and mixed forms of dementia), accompanied by impairments of memory, concentration and thinking, fatigue, lack of motivation and motivation, affective disorders;
• rehabilitation period of ischemic stroke;
• cerebral atherosclerosis;
• chronic cerebrovascular accidents;
• encephalopathy: atherosclerotic, post-traumatic, diabetic, toxic;
• consequences of encephalitis;
• asthenodepressive conditions;
• mental retardation, cerebroasthenic syndrome, minimal brain dysfunction in children;
• chronic alcoholism;
• age-related disorders of higher nervous activity, mental performance and memory;
• a state of chronic stress, accompanied by a decrease in higher mental functions;
• disturbances in memory, concentration and thinking;
• lack of motivation and decreased motivation;
• disorders of neuropsychic development in children.

Directions for use and dosage: Newborns: from the 3rd day after birth, 1 ml of suspension per day for a month, the dose is taken in the morning. Starting 2 months after birth, this dose is increased by 1 ml every week until the daily dose reaches 5 ml (1 teaspoon). Children from 1 year: ½ - 1 teaspoon of suspension 1-3 times / day (from 50 to 300 mg of pyritinol dihydrochloride monohydrate per day, depending on indications). Children from 7 years: ½ - 2 teaspoons of suspension 1-3 times / day (from 50 to 600 mg of pyritinol dihydrochloride monohydrate per day, depending on indications). The drug should be taken during or after meals. For sleep disorders, the last daily dose should not be taken in the evening or at night.

Adults: 2 teaspoons of suspension 3 times a day (600 mg of pyritinol dihydrochloride monohydrate per day). The duration of therapy depends on the clinical picture of the disease, at least 8 weeks and can be continued if necessary. As a rule, therapeutic success is achieved after 3-4 weeks of treatment. The optimal effect usually occurs after 6-12 weeks. In newborns at high risk of developing perinatal CNS pathology, the average duration of treatment is an average of 6 months. After 3 months, you should check whether there are indications for further treatment.